NcXHF

BIOLOGIC THERAPIES IN COLORECTAL CANCER
tastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised
controlled trial. Lancet. 2008;371:1007-1016.
12. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy
and surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC 40983): long-term results of a
randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208-1215.
13. Nasti G, Piccirillo MC, Izzo F, et al. Neoadjuvant FOLFIRIbevacizumab
in patients with resectable liver metastases from colorectal cancer: a
phase 2 trial. Br J Cancer. 2013;108:1566-1570.
14. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine,
and oxaliplatin as neoadjuvant therapy for patients with potentially
curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-
1835.
15. Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus
mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver
metastases from colorectal cancer: the OLIVIA multinational randomised
phase II trial. Ann Oncol. Epub 2014 Dec 23.
16. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic
response and protects against hepatic injury in patients treated
with oxaliplatin-based chemotherapy for colorectal liver metastases.
Cancer. 2007;110:2761-2767.
17. Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to
bevacizumab-containing chemotherapy in patients with colorectal liver
metastases and its correlation with survival. Surg Oncol. 2012;21:309-
315.
18. Klinger M, Eipeldauer S, Hacker S, et al. Bevacizumab protects against
sinusoidal obstruction syndrome and does not increase response rate in
neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Eur J Surg Oncol. 2009;35:515-520.
19. Turan N, Benekli M, Koca D, et al. Adjuvant systemic chemotherapy
with or without bevacizumab in patients with resected liver metastases
from colorectal cancer. Oncology. 2013;84:14-21.
20. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or
without cetuximab in patients with resectable colorectal liver metastasis:
the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:
601-611.
21. Nordlinger B, Poston GJ, Goldberg RM. Should the Results of the New
EPOC Trial Change Practice in the Management of Patients With Resectable
Metastatic Colorectal Cancer Confıned to the Liver? J Clin Oncol.
2015;33:241-243.
22. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic
resection after neoadjuvant therapy for nonresectable colorectal. Ann
Surg Oncol. 2001;8:347-353.
23. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal
liver metastases downstaged by chemotherapy: a model to predict
long-term survival. Ann Surg. 2004;240:644-657; discussion 657-658.
24. Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab
plus chemotherapy for patients with KRAS wild-type unresectable colorectal
liver-limited metastases. J Clin Oncol. 2013;31:1931-1938.
25. Garufı C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated
irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant
chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer.
2010;103:1542-1547.
26. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and
secondary resectability of colorectal liver metastases following neoadjuvant
chemotherapy with cetuximab: the CELIM randomised phase 2
trial. Lancet Oncol. 2010;11:38-47.
27. Venook A, Niedzwiecki D, Lenz H, et al. CALGB/SWOG 80405: analysis
of patients undergoing surgery as part of treatment strategy. Ann
Oncol. 2014;25:1-41 LBA10.
28. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment
and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:
1023-1034.
29. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to
oxaliplatin-based fırst-line combination chemotherapy for treatment of
advanced colorectal cancer: results of the randomised phase 3 MRC
COIN trial. Lancet. 2011;377:2103-2114.
30. Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and
anti-EGFR monoclonal antibody survival benefıt in metastatic colorectal
cancer: a meta-analysis of randomized, controlled trials. Ann Oncol.
2015;26:13-21.
31. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized,
multicenter phase II study of panitumumab plus modifıed fluorouracil,
leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus
mFOLFOX6 in patients with previously untreated, unresectable, wildtype
KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32:
2240-2247.
32. Hurwitz HI, Yi J, Ince W, et al. The clinical benefıt of bevacizumab in
metastatic colorectal cancer is independent of K-ras mutation status:
analysis of a phase III study of bevacizumab with chemotherapy in
previously untreated metastatic colorectal cancer. Oncologist. 2009;
14:22-28.
33. Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF
gene mutation status on outcomes from the phase III AGITG MAX
trial of capecitabine alone or in combination with bevacizumab and
mitomycin in advanced colorectal cancer. J Clin Oncol. 2011;29:
2675-2682.
34. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med. 2004;350:2335-2342.
35. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination
with oxaliplatin-based chemotherapy as fırst-line therapy in metastatic
colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:
2013-2019.
36. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab,
and mitomycin in fırst-line treatment of metastatic colorectal cancer:
results of the Australasian Gastrointestinal Trials Group Randomized
Phase III MAX Study. J Clin Oncol. 2010;28:3191-3198.
37. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine
versus capecitabine alone in elderly patients with previously
untreated metastatic colorectal cancer (AVEX): an open-label, randomised
phase 3 trial. Lancet Oncol. 2013;14:1077-1085.
38. Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan
versus irinotecan alone for patients with KRAS wild-type,
fluorouracil-resistant advanced colorectal cancer (PICCOLO): a
prospectively stratifıed randomised trial. Lancet Oncol. 2013;14:749-
759.
39. Hong D, Morris V, Fu S, et al. Phase 1B study of vemurafenib in combination
with irinotecan and cetuximab in patients with BRAF-mutated
advanced cancers and metastatic colorectal cancer. J Clin Oncol. 2014;
32:5s, (suppl; abstr 3516).
40. Corcoran R, Atreya C, Falchook G, et al. Phase 1-2 trial of the BRAF
inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF
V600 mutant colorectal cancer (CRC): updated effıcacy and biomarker
analysis. J Clin Oncol. 2014;32:5s (suppl; abstr 3517).
41. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination
with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously
treated metastatic colorectal cancer: results from the Eastern
Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-
1544.
42. Tabernero J, Cohn A, Obermannova R, et al. RAISE: a randomized,
double-blind, multicenter phase III study of irinotecan, folinic acid, and
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e205